Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by University of Sao Paulo.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT00681980
First received: May 19, 2008
Last updated: February 12, 2009
Last verified: February 2009

May 19, 2008
February 12, 2009
February 2008
September 2009   (final data collection date for primary outcome measure)
Neurological sacles [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00681980 on ClinicalTrials.gov Archive Site
Quality of life [ Time Frame: 2009 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)
Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil

Is the valproic acid efficacy to treat TSP/HAM

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Paraparesis Spastic Tropical
  • Drug: Valproic acid
    15 mg/kg/day
  • Drug: costicosteroids
    metypredsolone 1 g/day
  • Drug: valproid acid plus corticosteroids
    valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
  • Experimental: A, 2, III
    Patients with side effects to corticosteroids
    Intervention: Drug: Valproic acid
  • Experimental: B
    patient with corticosteroids
    Intervention: Drug: costicosteroids
  • Experimental: 3
    Valproic acid and corticosteroids
    Intervention: Drug: valproid acid plus corticosteroids
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
December 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HTLV-1; TSP/HAM fulfill criteria

Exclusion Criteria:

  • Age <18 years
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT00681980
278
No
Jorge Casseb, IMTSP
University of Sao Paulo
Not Provided
Not Provided
University of Sao Paulo
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP